MammoRisk® is the first solution developed by Predilife, designed for stratified breast cancer screening. This software is based on a scoring tool that uses discriminant criteria combined with a genetic test. As Predilife states in its press release, “MammoRisk® is being used in the MyPeBS clinical trial, funded by the European Union, which is investigating the benefits of stratified screening compared with standard screening. It involves 53,000 European women aged between 40 and 70 who are being monitored over a four-year period. The results, expected in early 2028, could lead to new official recommendations regarding breast cancer screening.”
Sorgem Évaluation supported Predilife in evaluating this predictive medicine solution as part of a strategic review relating to its commercialisation, following the completion of the MyPeBS clinical trial.
The consultancy therefore provided advice on the royalty rate that could be charged in return for the licensed use of the software by a third party.
Article précédent 